Kevin Franciotti, Reilly Capps, Celeste Alvarez, Danielle Nova, Rick Barnett, Juliana Mulligan
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case
Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper
Psilocybin research journey: investigating its use for treating tobacco addiction. Includes pilot study, comparative efficacy study, and upcoming multi-site clinical trial funded by NIDA.
Substance use disorder cases doubled during the pandemic, with over 100,000 drug overdose deaths in 2020. Research explores psychedelic-assisted therapy as a potential paradigm shift in addiction treatment efficacy.
Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks
Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.
Philippe Lucas
Psychedelic research faces challenges balancing methodological rigor with preserving subjective experiences in clinical trials, aiming to avoid bias while capturing the full impact of psychedelics on participants.
Ingmar Gorman, Erika Dyck, Tehseen Noorani
The POIESIS study explores how self-identity dimensions influence preferences in a psychedelic dosing environment. Initial findings show stronger connections to spiritual/religious identity compared to racial/ethnic identity. Ongoing efforts aim to
Cody J Wenthur
Psychedelic retreat centers are operating worldwide, with Oregon and Colorado preparing to regulate similar centers. These venues offer access to psychedelic experiences outside clinical settings, raising questions about their differences
Alexandra Pallas, Melissa Stangl, Ann “Annie Oak” Harrison
Artificial Intelligence and psychedelics share complexities as powerful tools impacting humanity's reality and choices. Understanding their potential and regulating them ethically are urgent imperatives for positive impact.
Alexander Beiner, De Kai
Dr. Bogenschutz presents quantitative findings from a psilocybin trial for alcohol use disorder, showing reduced alcohol craving and improved mood and cognition. Dr. Agin-Liebes discusses qualitative results on self-awareness and
Gabrielle Agin-Liebes
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.